ro cxforétub com/BIOTECHAGORERIBRKCAIUPSALOXFS108/7hrirue Biotech Scientists Discover “Magic Keys” to Immortality? A tiny U: ete coat eases aalntersed tel sete s] to take action today are looking at enjoying centuries of eee cclam a ~ S LEND= Aw \ Come Dear Reader, : 3 Se owt so¥ v onde new genetic treatment is changing everything we ki ‘af about life, aging y(oe"and the future of the human race. yo It involves a breakthrough medicine... one that goes deep inside the inner \ jorkings of our cells. ae aia sayene \ \ This process doesn’t just treat the symptoms of old age. Rather, it actually | steps and reverses the aging process itself. Se OQina shor my BA Poke cs (i yeh i “Cambridge University geneticist Dr. Aubrey de Grey, after months of Bos these treatments, concluded... Vo se “Whether they realize it or not, barring accidents and suicide, most a ral people can expect to live for centuries.” ow vit ae K wit And Reuters reports that, thanks to these medicines... ee 0 et ( a |, Doctors... have all the tools they need to cure aging — banishing . liseases that come with it and extending life indefinitely.” Aber reviewing these genetic breakthroughs, Reason magazine reports... Ar Text “By the end of this century... great-great-great-grandma, at 150 years Ss 5 old, will be as vital, with muscle tone as firm and supple, skin as opr o.oxordc bs com/BIOTEC H¢GORERIGRKCAIUPSA1.OXFS108/%- tue122016 ro oxordcisb com/BIOTECH49ORERIBRKCAIUPS4LOXFS108/7rtrue elastic and glowing, as her 30-year-old great-great-great- granddaughter with whom she’s playing tennis.” This medical advancement is not science fiction. Nobel Prize winner Dr. Philip A. Sharp called the initial discovery... “The most important and exciting breakthrough of the last decade, perhaps multiple decades.” And here’s where it gets really interesting... ae: me Just one company stands to make the lion’s share from Ae radical life-extension phenomenon... It's locked down nearly every patent behind its particular technology. The founder of this company, a Nobel Prize-winning scientist, is the same man who founded one of the most storied biotech companies ever. His first biotech outfit saw its stock go from $3.08 a share to over $396.91 a share. That's when his company developed and released a treatment for a debilitating — and often deadly — disease. He aie gave investors a gain of 12,580%. Wa yor gy dors onal now 9 ai Now he's doing it all over again at a brand-new company, with a G # breakthrough medicine about to extend the lives of thousands of Americans. With this latest venture, he’s set to create even bigger fortunes for his investors... ee Those who act now are looking at an opportunity to bank 20 years’ worth of stock gains in just a few short months. Here’s why... In the next 90 days, we're expecting an unprecedented and shocking announcement from this gentleman's new “startup” biotech company... It's a “coming out party” of sorts for this technology. hit. oraoxtordelse comvBIOTECH490RERIERKCAIUPSALOXFSIG8h=tue122016 ‘pro oxfordclub com/BIOTECH49ORERIERKCAIUPS4LOXFS108/7h= true And when this news hits the mainstream media, | believe it could become the most talked about technology breakthrough of our lifetimes. And the stock is likely to storm up the charts as a result. a o veoenof lll get into exactly what that announcement will be in a moment. But | think the bottom line is pretty clear: This company’s technology is launching an entirely new era of human history. One that's free from cancer and heart disease... free from nursing homes and the indignities of old age As I'll show you, the science is real. The demand is real. The treatments are real. And one company’s stock is about to skyrocket as this story hits the mainstream. For you and me, this means we get a rare chance to grab ahold of the next megatrend: one that could mint more millionaires than the Industrial Revolution and Internet combined. But only if we act right away. Here's everything you need to know to take full advantage of this ( remarkable situation... owe ov Yanch € Your Ticket to Centuries \yod : of Health and Wealth My name is Laura Cadden. I've been involved in the financial publishing business for nearly a decade. Today, I'm Associate Publisher of The Oxford Club, one of the world's most powerful fellowships of private wealth seekers. Our Club Members and analyst contacts include hedge fund managers, world-renowned scientists, CEOs, engineers, international speculators, Washington insiders, professors, entrepreneurs and doctors from across the world. Without our connections and inside sources, it would be impossible for us to teport this world-changing event... months before mainstream publications. terol delut comvBIOTECH4SORERIBRKCAUPSHLOXFS 1087=tuesr127016 ro oxfordlub convBIOTECHAGORERIERKCAIUPS4LOXFS108/7=tue I'm talking about one company’s scientific achievement that is poised to create billions of dollars in new wealth. This all-natural treatment has the potential to free us from just about every other kind of disease you can imagine... perhaps extending our lifetimes by centuries. As best-selling author and Google Chief Engineer Ray Kurzweil writes: “We've already started to reap the fruits of this new knowledge. We now have the means to dramatically reduce the risks of our biggest killers, heart disease and cancer, and to dramatically slow down the aging process itself.” So let me share with you exactly how this treatment works... “The Greatest Medical Advance Since the Discovery of Antibiotics” New Scientist When we are young, our cells are nearly perfect. They have just the right amount of elasticity and strength. They are able to self-regulate with more precision than a Swiss watch. And our cells can repair themselves automatically. This makes our skin, eyes, ears and everything else look and function well. However, as time moves along, these perfect cells split to create almost identical replacement cells. The key word is “almost.” Even though one cell is nearly indistinguishable from the next, the replacement cells have tiny imperceptible imperfections. At first, this makes no difference, but as time moves on, slowly these imperfections start to add up. They become more and more pronounced, and eventually they become so damaging that all the replacement cells itp. cxfordcivs com BIOTECH 2ORERIBRKCAIUPSAILOKFS 1087-12 408122016 ro.axordclub com/BIOTECH4GORERIBRKCAIUPSALOXFS108/79=tue become weak and frail... With RNA Interference, scientists believe they can reverse the effects of aging. In fact, they believe the first person to live to age 1,000 is alive right now, and probably 60 years old. This development will create billions in profits for one small biotech company located in Massachusetts. This damage results in cancer, heart failure, hearing loss, Alzheimer’s... almost all the worst diseases. Think of your cells as tiny photocopiers. Even if you have the highest-quality printer in the world, there will be a problem if you make copies of copies of a photograph. The little imperfections add up. Eventually, you won't even recognize the image. But, consider if you just used the original every time you wanted a copy. Then you could make perfect replicas for years and years. That's wi I ny’ Its scientists have found a way to get the “original” makeup of a cell. Its itor oxfrdelus com/BIOTECHA9ORERIGRKCALUPSSLOKFS1087h=tuesi22016 Pro.oxfordclub conv/BIOTECH4OR ERIGRKCAIUPSAILOXFS 108/%= true treatments convince the body to use the originals only, and to destroy any damaged “replacement” copies. ~ F 2d The industry term for this medicine is “RNA Interference.” } ie Biologically, it works like this... RNA is a messenger, copying genes from an old cell to a new cell. But what happens when RNA starts transmitting imperfections to the new cells? The answer is what we call aging: when these imperfections add up and our body starts breaking down. But “RNA Interference” stops the RNA from passing along these imperfections. It interferes with these mistakes, so your genes pass along only the blueprint of the original “perfect” cell. In other words: All your new replacement cells can be as perfect as the original cells As Dr. Gregory Hannon of Cold Spring Laboratory, New York, puts it: “RNA Interference could be used to... rejuvenate a tissue or organ... [and] for combating symptoms of aging.” That's why M.I.T.’s academic journal, Technology Review, lists RNA Interference as one of the... “Ten emerging technologies that will change your world.” And leading scientific magazine New Scientist calls it: “The greatest medical advance since the discovery of antibiotics.” Because what this company has discovered goes far beyond slowing and even stopping the aging process. It may be that it's discovered a universal cure for everything. I'm talking pp oxford com/BIOTECH«SORERIERKCARUPS4LOXFS1087htrue122016 10 oxford com /BIOTECH4SORERIBRKCAIUPSALOXFSI00°%=tt0e about the potential to wipe out every disease... including what we now call “old age.” That's why | wanted to tell you about this as soon as possible. Because, very soon, this company is going to make a very big announcement regarding this technology. It will bring all of this to the attention of the mainstream media for the very first time. Think about what happens next... News stories on the cover of Time... hour-long segments on 60 Minutes... op-eds in The New York Times and The Wall Street Journal about what this company’s work means for humanity... That's why you have the chance to as much as triple your money in just a few days from this situation, with a historic chance at over 70 times your money over the long term. But only if you act now. I'll show you how ina moment. First, let's take a closer look at how this breakthrough will radically alter how we look at healthcare... The Biggest Killers of Americans... One Common Cure? Right now, doctors treat you by working from the outside in — using either invasive drugs or surgery. But using RNA Interference, it’s possible to treat disease by going inside out. That's because this technology makes it possible to “turn off" harmful genes. For example, let's say one tiny cell in your body begins producing cancerous cells. With RNA Interference, doctors can keep the cancer cell from ever reproducing. In other can r insi lis before i In fact, if any genes are a problem for your body, this technology can just switch them “off.” tite pro.cxfor dtu com BIOTECHASORERIBRKCAIUPSLOXFS 108h=t1ue 12s22016 (bro orfordciub.com/BIOTECH 49ORERIBRKCAIUPSAILOXFS108°7%=true_ The same goes for viruses. Doctors can use RNA Interference to flip a “switch” inside the virus and, boom, the virus dies. What does this mean for you? Well, it means doctors will soon “switch off” health problems before they can hurt you. And it means billions in profits for the one company offering this treatment... as well as millions of dollars for its investors. Consider the sheer amount of money a company could make by curing... Heart Disease. It's the leading cause of death for Americans, killing almost 560,000 of us every year, or one of us every 23 seconds. WebMD says this costs Americans $444 billion per year. But thanks to nterf ll forms of heart di n_ be com purged from the body at the cellular level — before they can even touch your heart, much less endanger it. Cancer. It kills 574,000 people every year and costs $202 billion worldwide according to the American Cancer Society. But with this new NA medicine, ifely and pain lis bef read. That’s without any need for chemotherapy or dangerous surgery. Very soon, liver cancer, breast cancer and prostate cancer will become distant memories, tossed into the dustbin of history like polio and smallpox. Stroke. It kills 129,000 people every single year. However, using therapies based on this breakthrough, the risk for strokes could be wiped clean from your body. Before there is any chance of danger. Perhaps with a single dose of this medicine. Alzheimer’s Disease. It takes the lives of 83,500 Americans. However, thanks to RNA Interference, your brain could be made immune to Alzheimer’s. Those already afflicted could see the damage reversed. tpipraxordcb com/BIOTECH4S0RERIBRKCAIUPS4LOXFSIO8/?m=tue a9)srazo16 ro.odordclub com/BIOTECH AGORERIERKCAIUPSALOXFSIO0 7b ue Millions of long-suffering Americans could leave nursing homes and enjoy their lives once again. Diabetes. It’s a top killer in the U.S., causing 69,000 deaths every single year. But with this technology, diabetes could be “switched off” in your cells. Your body would be shielded from any further harm. Damage caused by this disease could be repaired, cell by cell. Now imagine the profits if a single company can cure ALL of these diseases — using its patented technology. And the examples | just gave are merely the top five killers of Americans. Right now, scientists are testing these treatments on everything from the bird flu to HIV. In short, this company’s RNA therapies are poised to absolutely transform the healthcare industry. No more painful surgery or dangerous drugs. Doctors will simply harness the same processes already at work inside your cells. Your body will naturally heal itself, from the inside out. No wonder the science behind this company's therapies won the Nobel Prize for medicine! It's also why Sir Paul Nurse, who won a Nobel Prize in 2001, stated... “Thanks to the incredible discovery of RNA interference, we think we should be able to crack the problem [of any disease.]’ That’s why this is the most powerful medical breakthrough we've ever seen at The Oxford Club. And we believe one company could hand you tens of thousands — if not hundreds of thousands — in investment returns in the months ahead. In my view, it will all start with the announcement I'll tell you about in a moment. But first, here’s the big question you're probably thinking about right now... hpsprecxterdclut.com/BIOTECHA9ORERIBRKCAIUPSALOXFS 1087h=tresri2016 pro.ovfordelub com/BIOTECHASORERIERKCAIUPSALOXFSIOB7=t'ue When will these treatments actually be available for Americans? Is this months away? Years? Decades? Well, the answer might surprise you... “A Gift From Heaven...” — Dr. Sharp, Nobel Prize Winner A few years ago, two scientists from the University of Massachusetts and the Carnegie Institute in Washington won the Nobel Prize in physiology and medicine for the discovery of RNA Interference. At that time, scientists also began testing RNA Interference on animals... » With worms, they learned how to use it to extend life spans by up to 30%. They figured out how to turn the fat insulin receptor gene in mice “off.” These mice could now eat ravenously yet remain fit and slim. Best of all, these lab mice didn’t get diabetes or heart disease, and lived 20% longer. ° With monkeys, they reduced bad cholesterol by 60% with a single dose of RNA Interference medicine... But when it comes to human beings, the health results are even more promising... Consider a 78-year-old woman from Ohio named Marty. As reported by PBS, Marty was diagnosed with macular degeneration, a disease causing blindness. Marty couldn’t play golf anymore. She couldn't play cards. She couldn't garden... because she couldn't even see the plants. Marty volunteered for one of the first therapies based on RNA Interference. Doctors gave her a single dose of the medicine... It began immediately reprogramming her cells to “switch off’ macular degeneration in her eyes. Then, when her body naturally created its replacement cells, the new cells lacked the imperfections. As a result - and incredibly soon — her eyesight came back... as good as new. ttto#praoxfordelus com /BIOTECHASORERIBRKCAIUPSALOKFS1087=t1ue 10729srr2216 ‘ro oxfordlub comvBIOTECHAGORERIERKCAIUPS4LOXFS108/7=t-ue As Marty told PBS, “/ can play bridge now... and see flowers once again!” Now, this early treatment will be a lifesaver for anyone suffering from vision loss. But that's just the beginning. As doctors apply this technology to hearing failure, osteoporosis, arthritis, skin damage and the rest, it might just free us from the suffering of aging altogether. No wonder Dr. Philip A. Sharp, Nobel laureate and professor of biology at MIT, calls this technology “a gift from heaven.” As Cambridge’s Dr. de Grey puts it, “This is not a matter of keeping people alive in a bad state of health. This is about preventing people from getting sick as a result of old age. Remarkably, all this is possible only because of the work of a small, American-based company near the campus of MIT. This unknown company has unlocked the secrets of RNA. At this very moment, it’s administering these treatments to hundreds of Americans... but those numbers could be on the verge of a dramatic rise. But in order to fully realize the financial potential of this situation, you also need to know the unusual story behind this stock... The Company Holding the Cure for Old Age The company I’ve been telling you about was founded by a scientist we'll call “Dr. Allen.” Dr. Allen is one of our greatest living scientists. In the ‘90s, he won the Nobel Prize for a different biotechnology, something called gene splicing. He's also a professor at MIT and a member of the prestigious Royal Society of London, which once included Sir Isaac Newton among its members. {nto orooxforcetub comsBIOTECHASORERIBRKCAIUPS4LOXFS 1087-100 1109sazm16 x0 oxfordelub cam B)OTECH49ORERIBRKCAIUPSALOXFS1087h=troe But beyond his many scientific credentials, Dr. Allen is also an incredible businessman. In the late ‘70s, he founded a company we'll call “Bio-Inc.” It was a tiny startup at the time, but today that company has over $10 billion in annual revenue. You'll be interested to know that Bio-Inc.’s stock is up more than 12,580% since Dr. Allen founded it. ee ee 4 Qo Ww Seo a a That’s enough to turn a modest $10,000 investment into almost $1,270,000. It's enough to turn a $100,000 investment into well over $12 million. The point is, Dr. Allen's passion is saving lives and making lots of money. That's what he does. He starts biotech companies to take advantage of Nobel Prize-winning science. He takes these companies public. Then he turns them into billion-dollar investments. In fact, this is exactly what he’s doing right now, at the company I've been telling you about... Right now, Dr. Allen's newest company is practically a “startup” in the world of biotechnology. It's certainly not a “penny stock.” However, with only a $9.59 billion market cap, it still has huge upside potential in light of the historic event I'll be showing you. And despite its relatively small size and obscurity, Dr. Allen's newest company controls one of the most valuable assets in the entire history of healthcare... wn rly all th lated IA I ferenct \ x we at N \ \ tpiarooxtor dete com BIOTECH OORERIBRKCAUPSALOKFS108/7h=trr 9sra20%6 pro.axfordclub.com/BIOTECH4SORERIBRKCAIUPSA/LOXFS108/%=true Dr. Allen's latest company has an advisory board made up of scientists from Harvard Medical School, MIT, Howard Hughes Medical Institute, Swiss Federal Institute of Technology and Koch Institute for Integrative Cancer Research. In just three months, this company will announce incredible medical results, which could shoot its stock to the \ moon. 4 \yt? \ pve iG ora That's right. The company has over 700 granted s worldwide for RNA © vy \ Interference. In total, it has over 300 granted or issued patents in the world’s \ sh WW major pharmaceutical markets — the United States, E.U., Japan... No other \/ company comes this close to completely controlling its technology. Of course, this is a huge deal in the biotech world. Owning the patents means no other company can sell or develop treatments based on its science unless it pays Dr. Allen's company first. This puts the company in an incredible position to earn its investors a great deal of money. That's why it’s arranging 30 licensing deals with pharmaceutical and biotech companies right now. And even more deals are expected soon... pspracxtr delve com/BIOTECHA9ORERIBRKCAIUPSHLOXFS108/7h=tre 1308san016 pro.ovordcltb com/BIOTECH 490RERIGRKCAIUPSAILOXFS 108/106 To understand how big these licensing deals can be for the bottom line, simply look at a company like SGX Pharmaceuticals. It set up a single licensing deal with Eli Lilly on July 8, 2008, and saw a 125% one-day jump in share price. tre % ii Kosan Biosciences set up a similar deal with Bristol-Myers on May 28, 2008, and saw its shares go up 229% in just one day. Meanwhile, the company we're talking about has 30 of these deals in the works. Having said that, these deals are still only icing on the cake for shareholders. The biggest windfall is only months away... Why an FDA “Loophole” Will Bring This to Market Faster Than Most Believe Possible This brings us to the world-changing event | mentioned earlier... In short, we believe as early as three months from now, we will witness an amazing event that will bring everything we've just talked about onto center stage. It will likely make this company very rich... and hand millions of dollars to the very lucky investors who know about it in advance. Very simply, Dr. Allen's company is on the verge of announcing incredible results from a Food and Drug Administration (FDA) study about its top RNA Interference medicine. Ce ep wir dyad This study, conducted with the Boston University School of Medicine, will be shocking even to most doctors. We know. We've seen the earlier FDA reports for ourselves. tmp: oroxfordelué com/B]OTECHA9ORERIERKCALUPSALOXFS 108/74 14922016 pro oxtordclub comBIOTECH 420RERIBRKCAIUPS4LOXFSIONM= tue The results of this announcement should lead to immediate Phase 3 approval from the FDA. Meaning... The First RNA Interference Treatment of Its Kind Will Soon Be Commercially Available in the U.S. This brand-new medicine will radically extend the lives of thousands of patients in the United States and around the world. It will also open up the doors to let many live for centuries... But when this event occurs, it will take even most mutual fund managers on Wall Street by surprise. And here’s why... Instead of introducing its medicine the traditional way, this company is exploiting a legal loophole created by the FDA. It’s called the Orphan Drug Act. You see, several years ago, Congress created this law to fast-track medicines that treat certain rare high-risk diseases. As The Wall Street Journal reports... “Incentives from the U.S. Food and Drug Administration to develop so-called orphan drugs can mean quicker approval, tax benefits for the developer and seven years’ protection from competition after approval.” Right now, getting full FDA clearance for a new medicine can take as long as 12 years. But like | said, Dr. Allen is a savvy businessman. That's why he and his management team are laser-focused on a treatment for a rare “orphan” disease. By taking this unusual route to get this medicine on the market, the company cut down the final approval time for its RNA medicine to as little as 12 months. Specifically, Dr. Allen's team is going after a terrible genetic disease that more than 40,000 people are diagnosed with each year. Most die from it itbsprocxfordclb corvSROTECH«SORERIBRKCAIUPSLOKFS08%htrv8 1809712016 procoxlrdelub com/BIOTECHA9ORERIBRKCAIUPGALOXFS1087h=true within three years. At this point, Dr. Allen’s company is winding down its Phase 2 trials treating this “orphan” disease. Which means the company is almost ready to make its biggest announcement yet about this technology. And based on early reports we've seen, after a single dose of this RNA medicine, patients had a 94% reduction of the protein that causes this genetic disease. In other words, most of the problems were “turned off’ after a single treatment. In addition, side effects were non-existent. As one doctor involved in the study reported... “! am impressed with the almost complete knockdown of [this disease] after just a single dose of drug.” When these results break into the mainstream in the days ahead, the federal government and FDA, according to its own Orphan Drug Act, will have no choice but to approve this medicine to get it to the, rherket as fast as possible. ni -\houe a po CMI That's why we fully expect this treatment will almost certainly pass into final Phase 3 testing in the next three months. And when the company announces this next stage of approval, this event alone could be worth I v Consider when Spherix Inc.\received approval from the FDA to start its final phase of testing for its new diabetes treatment, Naturlose. Its stock nearly tripled in one day... \ ( J \ on Are = (.. vu < ipsa cxfrdcivo com BIOTECH 490RERIBRKCAIUPSSILOKFS108%h=true 1879sri22016 ro.oxfordctub com/BIOTECHAGORERIBRKCAIUPS4LOKFS108/7=true Phase 3 Approval Announced 2005 Dec 5 Dec 12 And when Sarepta Therapeutics announced positive data from a similar FDA test, its shares immediately jumped 188% on the news... Announced Moving to Final Stage of FDA Testing... 2012 Sept 10 Sept 17 Sept 24 Oct I Oct 8 But those examples are just a taste of what we're expecting here... A Monopoly on the Important Scientific Breakthrough of a Generation pif. cxfrdetut cam /BIOTECHASORERIBRKCAIUPSALOKFS1087m=1100 v8ssra016 pro cxfordlub com /BIOTECHA9ORERIBRKCAUPSALOXFS100/2h= Ive What happens if this company gets final FDA approval for its RNA treatment, perhaps as early as next year, and brings it to the market? First off, instead of a three-year death sentence, these 40,000 patients each year may have their lives extended longer than ever thought possible - thanks to Dr. Allen's company. And this alone will likely generate billions of dollars in new sales. Second, because this will be the first major RNA Interference treatment to hit the market this way... and because it owns virtually all the patents on its technology, thi i vil nopol hi li lent. The door will be wide open for brand-new medicines developed by Dr. Allen and his scientists. In fact, they're working on five new treatments as we speak. New RNA therapies for cardiovascular disease, liver cancer, hemophilia and respiratory tract infections. All are in various phases of FDA approval right now. The results of these early FDA studies are extremely positive. In fact, we expect to see the first of these other RNA medicines hit the market within 24 months. Think about the potential here. The hopes of millions of Americans are certainly riding on these new treatments. Consider the global market for liver cancer drugs will exceed $2 billion. And the world market for cardiovascular drugs will exceed $111.8 billion by the year 2015. 3 aaa) Each of these new medicines could be worth billions more in additional revenue for this company. And ri ber, first time Dr. Allen hi In 1996, at Bio-Inc. (the first company he founded), Dr. Allen used the Federal Orphan Drug Act to secure FDA approval for a drug called Avonex. Today, this drug is worth nearly $3 billion. Meanwhile, Bio-Inc. saw its shares go from $3.08 a share to over $396... an nipspraoxfrdlob con fBIOTECHAPORERIBRKCAIUPSALOXFSIO8T=Irue 1920srt p10 oxordlub com/BIOTECHSORERIBRKCAIUPSALOXFSI087h=true increase of 12,580%. Dr. Allen’s done it before. And that’s why | have no doubt he will do it again with RNA Interference. Two Chances to Make Life-Changing Profits Quite frankly, there is no calculating how high the stock will go once the company gets its final approvals for this miracle of medicine. Just consider... « Acompany called Amgen announced its human-protein therapy passed FDA trials. As a result, the stock soared an astounding 20,031%. « When Celgene's cancer-treatment drug cleared the FDA, it ignited a stock run worth an incredible 25,100% today. Then there's a company called Biogen. It cleared its new multiple- sclerosis drug through the FDA, and investors have since pocketed 7,806%. But more than this, the publicity surrounding these medicines will finally put this company in the public eye. Remember, Dr. Allen's company will now have FDA approval to “switch off” genes inside our cells. In short, this company will then have the demonstrated scientific capability — and the governmental approvals — to let us live for centuries. And if this doesn’t get you excited as an investor, my friend, I'm not sure what will. However, in order to make the most money, you need to get into this stock right now. At the very least, you need to get in before the first major announcement, which will hit as early as three months from now. Doing so will give you as many as two chances to make a lot of money fast: 4. You get your first and best chance, before the announcement of the Phase 3 trial that could happen in the next three months. As | said, if per oxford com BIOTECH 4SORERIBRKCAIUPSALOKFSIO8%h=trve 1979sr22016 pro oxforectub comBIOTECH42ORERIERKCAIUPSALOXFSI087=true you want to make the MOST profits, you need to get in before this announcement. 2. You also get a second chance: before the announcement of the full FDA approval that might go public in as early as 12 months. If you get in before this final approval, you'll stand to make an incredible amount of money. However, based on what we've seen in the past, you won't make as much as those who took the initiative to get in early. This is why | wanted to send this message to you as soon as | possibly could. This company won't remain overlooked for much longer. When it announces the final FDA trials — perhaps in just a few months — there will be no stopping this stock. It's only a matter of time before the national media starts to put the pieces together. Finding a real “fountain of youth” will set imaginations on fire. Every new cure will make the headlines. Millions of individual investors and their mutual fund managers are sure to begin piling into the stock. We're just a short time away from this watershed event. That's why I've compiled a complete research report called “The RNA Interference Revolution: Your Ticket to Centuries of Health and Wealth.” « Itreveals everything you need to know — right down to the stock symbol of Dr. Allen's newest company and the complete timeline of FDA approvals. e You'll get a full overview of the science behind RNA Interference... all in plain, easy-to-read English. « And of course, you'll find out how to make the most money. Because we'll recommend how to play each impending FDA announcement for the greatest profit advantage with minimal risk. You'll know with confidence when to get in and when to get out. And you won't pay a dime for this intelligence. Because I'd like to send you all of this free of charge, simply for taking a trial subscription to the Club's npr. oxtr delve conmIOTECH42ORERIERKCAIUPSALOKFSIO8%=tue 2008122016 prooxlordelub com/BIOTECHASORERIBRKCALUPSALOXFS100°%=trve flagship newsletter, The Oxford Communiqué. (woot Ae. 4 wit We don't chase after trendy stocks or take undue risk. Instead, in our Oxford Communiqué, we follow a tried and. 4rde strategy. We're into high-yielding income investments, momentum stocks, special precious metals situations, undervalued real estate plays and many more lucrative — but extremely safe - investments. We offer our readers special strategies on avoiding taxes and accessing shared business opportunities among Club Members and in-depth research from our hand-selected Pillar One Advisors. We use our vast “expert network” of contacts on Wall Street and around the world to give us insider intelligence on where the smart money is moving. Finally, we follow an unusual worldview, which ensures we almost always make money... A Worldview That Makes You \' N AM 5 Money No Matter What xv Ss Now, we recognize that we can’t control what goes on in Washington or with entitlements like Social Security. That's why we don’t rant and rave about politics like many of our competitors. You won't find long essays about why this political party is always wrong. You won't find us gazing into crystal balls to predict doomsday. We don't have axes to grind. Instead, our team of experts, led by Chief Investment Strategist Alexander Green, spends 100% of its efforts looking for investments and strategies to help our readers make the most money right now... no matter what's going on politically or economically. As Alex likes to say, “! can’t predict what crazy thing the politicians will do next, but | can tell you the one universal truth of investing. If the company makes money and lots of it, the price of the stock will go up... Without exception.” It's not that we don’t watch the markets like a hawk for every opportunity. We most certainly do. But we don’t worry about things outside of our control — itppr oxford con/BIOTECH SOORERIBRKCALUPSALOKFS106/?h=tue 2109sraa016 prooxfordlub comBIOTECH4SORERIERKCAIUPSALOXFS100/=1102 because we're too busy making money, Perhaps that’s the reason why, since 2000, our Communiqué's Oxford Trading Portfolio has delivered an 8.4% annualized gain — more than double the S&P or the Dow. Or why, as | write this, 29 of the 31 open recommendations in our model portfolio are up, with an average gain of 65.37% per position. Or why the independent Hulbert Financial Digest has consistently ranked us among the top-performing newsletters for over a decade. Over the last 20 years, we've helped our Members thrive through virtually every major market turn... e In 1999, at the height of the dot-com craze, we sent out a special report to Members, warning, “We are at the peak of most likely the greatest financial mania ever witnessed. Investors in the hot tech and net stocks could see their investments nearly wiped out.” Over the next two years, the Nasdaq lost 78% of its value, but our readers were safe. Instead of riding the dot-com collapse, we shifted strategies to the ultra- cheap commodities markets. We recommended gold and hard-asset stocks like Fording Canadian Coal and BHP Billiton, which jumped 267% and 263%, respectively. In January of 2008, nearly nine months before the financial crisis struck, we warned our readers, “the housing market is going through an adjustment like no one has seen in the past 100 years.” We closed out of all but one single position in our portfolio that year, and actually posted Vi ain of 28% whi crumbk Ir Then, in 2009, Alex called the exact bottom of the market in a message to Members, saying, “2009 will be a terrible year for the economy. But, shocking and surprising most investors, it should be an excellent year for the stock market." The stock market went on to jump 65% by year’s end. And some o' readers ro thanks 's forecast. hpsproosfr delve com BIOTECH #OORERIGRKCAIUPSALOXF'S10807h=true zns22016 procxfordelub com/BIOTECH420RERIBRKCAUUPSALOXFS1087h=!roe Joe Martin of California, for example, emailed to tell us he made over $1.3 million thanks to Alex's market calls. “The bottom in 2008 was $1,400,000. Yesterday, | was at $2,741,000... The point is that when | was at the bottom, [you] gave me the courage to stay in the game,” Joe tells us. Nevertheless, while our market calls and overall solid performance have helped our Members grow their wealth steadily over many years, it's the rare technological breakthroughs like RNA Interference that are the true game changers. You see, every once in a while, a “disruptive” technology comes along that nobody Nr This tec! hed Ao whil e's of gains We've been a part of most of these technological revolutions over the years... « Like when we recommended Celgene, a developer of life-saving cancer treatments. Reader Mike Adams from San Angelo, Texas, wrote in to say he made 122% on this play. Or when Alex recommended Riverbed Technologies, a key creator of cloud computing technology. It handed Members a gain of 134%. Or when Chief Income Strategist Marc Lichtenfeld developed a new supercomputing system for picking stocks. The very first pick he made using the system was Cardtronics. It handed readers a gain of 130% in less than a month. The situation we've uncovered today is no different... In fact, it’s likely much better. Why? Because RNA Interference will not just “disrupt” many of the most lucrative drug markets. It will also completely transform global healthcare... and alter our very way of life. That's why when you become a new Oxford Communiqué subscriber, our titer oxford comIBIOTECHA2ORERIBRKCAIUPSALOXFSION= tes22016 ro oxtordctub.com/BIOTECHsSORERIBRKCAIUPS4LOXFS 108/7h= true first order of business will be sending you our in-depth private briefing, “The RNA Interference Revolution: Your Ticket to Centuries of Health and Wealth.” i But this is just for starters... ae d cr cS + The Secret to Making 453% f ee a in the Next Few Years oy In addition to our play on RNA Interference, we're looking at several other lucrative opportunities right now. These include some of our best ways to make sure your wealth increases in value, no matter what the markets end up doing this year. For example, here's a rather unusual opportunity to pocket big gains from another “disruptive” breakthrough... ° “Hypet The Patented Solution to Our $1.5 Trillion Problem’: There's a serious epidemic growing in America right now. It involves the massive explosion in Wi-Fi usage. And the problem is simply that the demand for wireless Internet is getting out of control... The number of people - and devices - using Wi-Fi is growing exponentially. To an unsustainable degree. With networks already struggling to maintain current data levels, something needs to change. Fast. Fortunately, there’s a small company out of California that’s already made significant strides down this road. But that's not all. Then there’s... “How to Collect 453% on Modern Society’s Essential Asset": Most Americans don’t know this, but a single commodity is poised to go ona big run right now. For one, it’s essential to almost everything we do, from storing data on a computer to starting up our cars. Secondly, it's extremely rare. The total world supply of this commodity would fit inside the average living room. Finally, it's historically inexpensive right now. The last time it was this cheap relative to gold, it promptly went on a 453% run. It's not oil, natural gas or anything else you might guess. You'll find out exactly what's going on in our latest special report. Lastly, this report is essential reading for all new Oxford Communiqué ipsa cxfordelub com /BIOTEC HéSORERIBRKCAIUPSAILOXFSIO8™M=t/ve 20081122016 ro cxfordlub com/BIOTECH42ORERIBRKCALIPSALOXFSI087H=IrvE subscribers. It's called... » “How to Build a Million-Dollar Portfolio From Scratch”: Successful investing involves seven real secrets. Almost all the world’s best investors use them... while the general public remains totally in the dark. In this special bonus report, you'll find out each of them and how they can help you build a million-dollar portfolio, starting with almost nothing. Best of all, you'll never find all seven of these secrets in any book, newsletter or magazine. You'll find them all only in this “for your eyes only” report. Of course, if you follow our strategy, your first investment will probably be the one company using RNA Interference to let us live to age 1,000. If you want to make a lot of money quickly, this is the very first report you'll want to read However, as a new subscriber of The Oxford Communiqué, you can get all our treasured investment secrets... you’ll know what we're researching right now... and you will know exactly where your money should be before most folks on Wall Street even have a clue. That's because along with your subscription to the Communiqué, you'll also be a Premier Member of The Oxford Club. And the point of our investment group is not simply to give you a one-time big gain and send you on your way. We'd like to help you develop and maintain a level of wealth and knowledge you wouldn’t have thought possible. But why am | so confident all this will work for you? We’re Only Successful if Our Members Are Successful |! can’t say for sure if The Oxford Communiqué is the right fit for you, but our readers certainly believe our work is better than anything else out there. Like subscriber Norma Weitz, who emailed us to say, “l want to let you know how pleased | am with all your recommendations. They have been so successful that | was able to itp pro oxordcb com/BIOTECHASORERIBRKCAILPS4LOXES 108/78 229sn22076 ro axfordclub com(BIOTECHAGORERIBRKCAIUPS4ILOXFS108/%h=Irue purchase a $100,000 annuity, which came from these stocks.” Or subscriber Gary Sensebaugh, whose only regret was not joining earlier: “L love your service and wish I'd discovered it 20 years ago. That would have saved me $500,000 and a sooner goodbye to Salomon Smith Barney.” Then there's longtime subscriber Mike Adams, who told us about his experience: “Some of my most successful Oxford picks over the years: Fording Canadian Coal, 151% profit... Aluminum Corp. of China, 150%... Celgene, 122%... Chesapeake Energy, 114%... ABB Limited, 97%... “Oxford gave me the knowledge and confidence to get started investing. | shudder to think where my finances would be were it not for the well-researched investment recommendations from Oxford.” | think you get my point. In the months ahead, we'd like to make sure you make the same kind of money as our many happy subscribers. Based on our long-term track record, you're likely to see investment returns ranging from 25% to 271%. Moreover, you'll get these returns with lower risk, through our Oxford Asset Allocation Model, and better tax-saving strategies (especially important in the current pro-tax environment). We'll send you our Oxford Communiqué advisory each month, detailing our hottest one or two market opportunities. You'll also receive password- protected access to our website, including details on current recommendations, special situations reports, invitations to Oxford Club events and much more. Between issues, we also offer weekly portfolio updates, free access to our daily e-letters and our sought-after weekly Market Wake-Up Call broadcast, with video messages regarding current market developments. tto:foreoxordclub com/BIOTECH49ORERIERKCAIUPSALOXFS1C8/htuesyra016 ro cxordlub com/BIOTECHA9ORERIBRKCALIPS4LOXFSIO87= Ue And if you ever have any questions or concerns, our Member Services Team is always just a phone call away. By now, I’m sure you're wondering how much a subscription costs. | think you'll be surprised... I hope you're considering trying us out. But with all these benefits, you may be worried the cost of our newsletter is some exorbitant fee. After all, I'm offering you the chance to make potentially thousands of dollars thanks to the miracle of RNA Interference. SPECIAL OFFER: Try The Oxford Communiqué for $4 a Month Fortunately, we're currently offering all the special reports I’ve mentioned — and Oxford Club Membership — at a special introductory price. Generally, a one-year subscription to The Oxford Communiqué costs $149) That's about $12 per month. Code TM eoxe¥ Considering the average person pays an estimated $2,583 per year in fees ub on their 401(k) account, I'd say this is more than fair. Mew 3 But since this is an urgent situation and I'd like you to receive this report ont Dr. Allen's company as soon as possible, today we are offering you a a subscription at the special price of $49. That works out to about $4 per month. To be frank, this is almost embarrassingly cheap. That's especially true for an organization with the heritage of ours. However, this low price is the best way we can both be sure we're the right fit for you By joining today, you'll get 12 monthly issues of The Oxford Communiqué, membership in the Club, access to all our specialized recommended portfolios, password-protected entry to our websites, weekly updates on our positions, our weekly Market Wake-Up Call videos and much more. Plus, we'll rush you all four of our special reports, including... « “The RNA Interference Revolution: Your Ticket to Centuries of hitppreoxfordsive com BIOTECH 490RERIBRKCALUPSALOXFS108/7h= tue 29122016 ro.oxfordelub comiBIOTEGHA9OR ERIBRKCAIUPS4/LOXFS108/7h=trUo Health and Wealth” ° “Hyper-Fi: The Patented Solution to Our $1.5 Trillion Problem” + “How to Collect 453% on Modern Society's Essential Asset” « “How to Build a Million-Dollar Portfolio From Scratch.” | really don’t think | could make this offer any easier. But just in case you have any lasting doubts, let me make a final suggestion... Go ahead and sign up right now. We'll immediately send you each of the promised reports via email and give you full access to all The Oxford Communiqué benefits. Then take your time and try us out. See if everything I've claimed in this message is true. The great thing is, if at any time over the next 60 days you feel The Oxford Communiqué is not right for you, we'll give you a full refund, Plus, you'll get to keep everything you've received so far — including the reports — as our gift to you. That's like trying out this research for FREE for the next 60 days... | can't say if a subscription to The Oxford Communiqué is what you are looking for to secure your financial prosperity. But there's just one way to find out... Simply click here to go to a secure order form. You'll have access to all of our research in a matter of minutes. Or, if you prefer, call 866.415.8492 or 443.353.4234 and mention priority code LOXFS108 to take advantage of this special offer. The way | look at it, you have two choices with your money right now. You can keep it all in regular stocks or mutual funds that, in the best-case scenario, return 12% per year, and in the worst-case scenario, offer zero returns over the long run — or even make you lose money, as most Americans do in the stock market. Or, by taking a few minutes of your time, you can make one simple move — tp. oxfordelva com/BIOTECH490RERIBRKCAIUPSALOKFS 105% true 2828sr2016 10 oxfordlub com/SIOTECHAGORERIBRKCATUPSALOXFS1087%=true ‘one that could create returns as high as 7,000% like we've seen in the past — and perhaps enjoy centuries of health and wealth. I'm hoping you'll make the right choice. Sincerely, aoa (tu Laura Cadden Associate Publisher, The Oxford Club May 2015 P.S. Remember, to make the most money, you need to take advantage of this opportunity right now. Once the news breaks about this technology, there will be no stopping this stock. Millions of Americans could start getting these radical life-extension treatments as soon as next year. And you can get everything you need to know in our special report — RISK-FREE — for the next 60 days, but only if you act now. Just click on the “Subscribe Now’ button below. Subscribe Now ipso fordeloh,comJBIOTECH4SORERIERKCAIUPSSOXFS108/7h=true